Drug Search Results
More Filters [+]

Lunacalcipol

Alternative Names: lunacalcipol, cta-018, cta018, cta 018
Latest Update: 2014-11-06
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: CYP24 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Topical,Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: OPKO Health
Company Location: MIAMI FL 33137
Company CEO: Phillip Frost
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lunacalcipol

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Kidney Failure, Chronic|Hyperparathyroidism, Secondary|Psoriasis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2007

P2

Withdrawn

Kidney Failure, Chronic|Hyperparathyroidism, Secondary

2013-07-01

CTA018-CL-2002

P2

Completed

Kidney Failure, Chronic|Hyperparathyroidism, Secondary

2010-02-01

CTA018-CL-2001

P2

Completed

Psoriasis

2007-05-01

Recent News Events

Date

Type

Title